SpirovacThis page contains information on Spirovac for veterinary use.
The information provided typically includes the following:
- Spirovac Indications
- Warnings and cautions for Spirovac
- Direction and dosage information for Spirovac
SpirovacThis treatment applies to the following species:
Leptospira Hardjo Bacterin
PRODUCT DESCRIPTION: Spirovac is for vaccination of healthy cattle 4 weeks of age or older, including those pregnant and/or lactating, for the prevention of infection by Leptospira borgpetersenii serovar hardjo, including reproductive and renal tract colonization, and urinary shedding for up to 12 months. Vaccination with Spirovac also aids in the prevention of fetal infection. Spirovac contains chemically inactivated whole cultures of L. borgpetersenii serovar hardjo-bovis.
DISEASE DESCRIPTION: Infection with L. borgpetersenii serovar hardjo (type hardjo-bovis), previously classified as Leptospira interrogans serovar hardjo, is the primary cause of leptospirosis of cattle in the United States1-2 and in much of the world.3 L. borgpetersenii serovar hardjo is also an important zoonotic disease causing a flu-like syndrome in humans and is recognized as an important occupational disease in many industrial countries.3 Cattle are the primary reservoir for L. borgpetersenii serovar hardjo, resulting in maintenance infections that are often chronic and subclinical in nature but that can cause economic loss to cow-calf and dairy operations.4
The disease is usually transmitted by direct or indirect contact with leptospira-infected urine or can be sexually transmitted. In calves, clinical signs of leptospirosis may include fever, prostration, loss of appetite, shortness of breath, anemia, and blood in the urine. In adult cattle, clinical signs include decreased milk production and reproduction loss, including abortions, stillbirths, weak calves, and infertility.4-7
SAFETY AND EFFICACY: The safety of Spirovac was demonstrated in field studies representing different management practices in three different geographic locations in the United States. A total of 1431 beef and dairy cattle were evaluated where 615 calves (224 calves were between 4 and 4 1/2 weeks of age) and 816 cows (804 were pregnant) were vaccinated according to label recommendations. Safety in each trimester of pregnancy was established in dairy cows: 212 cows in the first trimester, 245 cows in the second trimester, and 144 cows in the third trimester. No systemic reactions or significant injection site reactions were observed in vaccinated animals.8
The safety of an overdose of a Leptospira Hardjo-Pomona Bacterin (formulated as Spirovac but also containing L. interrogans serovar pomona) has been satisfactorily demonstrated in pregnant cattle. Ten pregnant cows in the first trimester of pregnancy were vaccinated with 6 times the recommended dose (twice the normal dose volume at three different injection sites). The cows were revaccinated in the same manner 28 days later. Despite the overdosing, only minor localized injection site reactions were observed, and no reaction exceeded 5.0 cm in diameter. No systemic reactions were observed and all ten cows were confirmed pregnant 30 days post second vaccination.8
Researchers at the National Animal Disease Center (NADC) of the Agriculture Research Service (ARS), USDA, Ames, IA, conducted 2 separate studies evaluating the efficacy of Spirovac against the colonization of the urinary and reproductive tract of cattle when challenged with virulent strains of L. borgpetersenii serovar hardjo-bovis.9,10 The NADC challenge strains used in the studies are reliable in their ability to cause urinary shedding and represent the most common strains in the U.S. In the first study, heifers were vaccinated twice and challenged 16 weeks post second vaccination with serovar hardjo type hardjo-bovis A by intraperitoneal inoculation or conjunctival instillation for three consecutive days. Urine samples were collected weekly and heifers were euthanized 11-14 weeks postchallenge. Kidneys were examined for evidence of colonization. Leptospires were not detected in any of the urine or tissue samples from the Spirovac-vaccinated heifers, whereas 6/8 nonvaccinated heifers shed leptospires in their urine and all 8 had evidence of renal colonization. In the second study, 12 Spirovac-vaccinated and 12 nonvaccinated heifers were challenged 18 weeks postvaccination by instillation of either serovar hardjo type hardjo-bovis A or type hardjo-bovis B into the conjunctival sac and vagina. Cattle were monitored to detect urinary shedding of serovar hardjo for 8 weeks after challenge and the presence of leptospires in the uterus and oviducts was determined at necropsy. Urinary shedding of serovar hardjo was not detected in any (0/12) of the cattle vaccinated with Spirovac. In contrast, nonvaccinated cattle became infected and shed serovar hardjo in their urine (12/12). Vaccinated cattle also were protected from colonization of the reproductive tract, whereas leptospires were detected in the uterus or oviducts of 10/12 control heifers.
The efficacy of Spirovac as an aid in the prevention of placental and fetal infection was established in a study conducted by researchers at the NADC and Michigan State University.8,11 Heifers were vaccinated two times prior to breeding, and challenged at mid-gestation with virulent L. borgpetersenii serovar hardjo by conjunctival and vaginal instillation. Heifers were monitored for urinary shedding until calving. Heifers and calves and cows were euthanized as soon as possible after parturition and urine samples, maternal kidney, placenta and fetal tissues were examined to detect the presence of leptospires. Urinary shedding of serovar hardjo was detected in all (8/8) nonvaccinated control heifers and in none (0/16) of the vaccinated heifers after challenge. Leptospires were detected in the placenta or fetal tissues of 5/8 control cattle, whereas leptospires were not detected in any of the placenta or fetal tissues of the 16 Spirovac-vaccinated heifers. Therefore, vaccination with Spirovac prevented fetal infection in heifers challenged at mid-gestation with L. borgpetersenii serovar hardjo.
To determine the efficacy of a Leptospira Hardjo-Pomona Bacterin (formulated as Spirovac but also containing L. interrogans serovar pomona) in young calves with maternally derived antibodies, a group of 12 calves from cows previously vaccinated were divided into 4 equal groups, with the first dose of Spirovac given at either 4, 6, 10, or 18 weeks of age and the second dose given 4 weeks after the first dose according to label recommendations. Seven seronegative calves from unvaccinated cows were used as a control group. All calves were challenged at 30-32 weeks of age. Microscopic agglutination titers (MAT) prevaccination ranged from 2 to 25, with maternal antibody titers observed for up to 13 weeks after birth. MAT titers were significantly higher in controls than vaccinates postchallenge. Serological titer rise in vaccinates were inversely proportional to prevaccination titers. Leptospiruria was not detected in any of the vaccinated calves but occurred in 71 percent of control calves within 21 days of challenge and in all controls by 35 days. This study showed that young calves vaccinated as early as 4 weeks of age were protected against a virulent challenge with L. borgpetersenii serovar hardjo-bovis.12
In a study conducted by researchers at the University of Massachusetts, NADC, and Michigan State University,13 Spirovac was demonstrated to induce a strong, sustained cell-mediated immune response against L. borgpetersenii serovar hardjo. Spirovac induced production of gamma interferon and strong antigen-specific proliferative responses by peripheral blood mononuclear cells beginning 2 months after the first dose of vaccine and continuing for the 7-month study period. These responses were absent from nonvaccinated control cattle. A cell-mediated immune response is associated with protection against L. borgpetersenii serovar hardjo.
Duration-of-immunity study: Twelve months duration-of-immunity was shown in a 54-week vaccination-challenge study. Eighteen 7- to 10-month-old calves were divided into 2 groups. Nine calves were vaccinated twice with Spirovac according to label recommendations at 4-week intervals and 9 calves were held as controls. The eighteen calves were housed together, held in isolation for 54 weeks, and subsequently challenged with L. borgpetersenii serovar hardjo-bovis. Spirovac was shown to protect 100 percent of the vaccinated calves against urinary shedding (leptospiruria). It was concluded that Spirovac could provide protection for at least 12 months when administered according to label recommendations to healthy animals.8
Directions For Use
1. General Directions: Vaccination of healthy cattle is recommended. Shake well. Aseptically administer 2 mL subcutaneously. In accordance with Beef Quality Assurance guidelines, this product should be administered subcutaneously (under the skin) in the neck.
2. Primary Vaccination: Healthy cattle should receive 2 doses administered 4-6 weeks apart. When used as an aid in preventing fetal infection, administer the second dose at least 2 weeks prior to breeding.
3. Revaccination: Annual revaccination with a single dose is recommended.
4. Good animal husbandry and herd health management practices should be employed.
1. Store away from light at 2°-7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.
2. Use entire contents when first opened.
3. Sterilized syringes and needles should be used to administer this vaccine.
4. Do not vaccinate within 21 days before slaughter.
5. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
6. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.
1. Thiermann, AB: Bovine leptospirosis: bacteriologic versus serologic diagnosis of cows at slaughter. Am J Vet Res 44:2244-2245, 1983.
2. Miller DA, Wilson MA, Beran GW: Survey to estimate prevalence of Leptospira interrogans infection in mature cattle in the United States. Am J Vet Res 52:1761-1765, 1991.
3. Leptospira and Leptospirosis. 2nd Edition. Eds. Faine, Adler, Bolin, Perolat. MediSci, Melbourne, Australia, 1999.
4. Large Animal Internal Medicine. 3rd Edition. Smith, B.P. Mosby, St. Louis, USA, 2002.
5. Slee KJ, McOrist S, Skilbeck NW: Bovine abortion associated with Leptospira interrogans serovar hardjo infection. Aust Vet J 60:204-206, 1983.
6. Dhaliwal GS, Murray RD, Dobson H, et al: Effect of vaccination against Leptospira interrogans serovar hardjo on milk production and fertility in dairy cattle. Vet Rec 138:334-335, 1996.
7. Ellis WA, O’Brien JJ, Neill SD, et al: Bovine leptospirosis: Experimental serovar hardjo infection. Vet Microbiol 11:293-299, 1986.
8. Data on file with APHIS, USDA.
9. Bolin CA, Alt DP: Use of a monovalent leptospiral vaccine to prevent renal colonization and urinary shedding in cattle exposed to Leptospira borgpetersenii serovar hardjo. Am J Vet Res 62:995-1000, 2001.
10. Bolin CA, Alt DP, Zuerner RL: Protection of cattle from renal and genital tract colonization with Leptospira borgpetersenii serovar hardjo. Proceedings of the XXI World Buiatrics Congress, 2000.
11. Alt DP, Hornsby R, Bolin CA: Use of a monovalent leptospiral vaccine to prevent placental and fetal infection in cattle exposed to Leptospira borgpetersenii serovar hardjo during mid-gestation. J Am Vet Med Assoc Submitted, 2002.
12. Palit A, Middleton H, Sheers J, et al: The influence of maternal antibody and age of calves on effective vaccination against Leptospira interrogans serovar hardjo. Aust Vet J 68:299-303, 1991.
13. Naiman BM, Alt DP, Bolin, CA, Zuerner R, Baldwin CL: Protective killed Leptospira borgpetersenii vaccine induces potent Th1 immunity comprising responses by CD4 and γσ lymphocytes. Infection Immun 69:7550-7558, 2001.
Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8471 (USA), (800) 461-0917 (Canada).
For veterinary use only
Spirovac® is a registered trademark of CSL Ltd. Australia
U.S. Veterinary License No. 190
Zoetis Inc., Kalamazoo, MI 49007
Presentation: 10 and 50 dose vials.
NAC No.: 36902123
333 PORTAGE STREET, KALAMAZOO, MI, 49007
|Every effort has been made to ensure the accuracy of the Spirovac information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2015 North American Compendiums. Updated: 2015-04-03